. 2017 Jan 12;7:40374. doi: 10.1038/srep40374

Table 2. Univariate and multivariate analysis of survival for 503 patients.

	N	Events	Univariate			Multivariate
	N	Events	OS (month)	95% CI	p	p	HR (95% CI)
Age
≤65	353	292	11.7	10.385–13.015	0.554
>65	150	129	11.0	8.750–13.250	0.554
Gender
Male	293	256	10.3	9.047–11.553	0.004	0.934	1.011 (0.773–1.323)
Female	210	165	12.7	10.581–14.819	0.004	0.934	1.011 (0.773–1.323)
Smoking status
Non-smoking	259	205	12.4	10.420–14.380	0.001	0.298	0.868 (0.664–1.133)
Smoking	243	216	10.6	9.193–12.007	0.001	0.298	0.868 (0.664–1.133)
PS score
0–1	477	398	12.0	10.846–13.154	0.024	0.015	1.691 (1.107–2.582)
≥2	26	23	4.0	1.626–6.374	0.024	0.015	1.691 (1.107–2.582)
Histological type*
Adenocarcinoma	435	359	12.0	10.656–13.344	0.033	0.784	1.045 (0.762–1.434)
Squamous	58	32	8.3	6.336–10.264	0.033	0.784	1.045 (0.762–1.434)
Disease type
Recurrent disease	135	101	14.2	12.450–15.950	0.001	<0.001	1.524 (1.205–1.927)
Local or metastatic disease	368	320	10.7	9.782–11.618	0.001	<0.001	1.524 (1.205–1.927)
EGFR
Mutation	184	133	17.5	15.055–19.945	<0.001	<0.001	1.717 (1.358–2.171)
Wild type	319	288	9.7	8.506–10.894	<0.001	<0.001	1.717 (1.358–2.171)
EGFR TKI therapy
Yes	244	192	14.8	12.3346–17.254	<0.001	<0.001	1.445 (1.170–1.786)
No	259	229	10.0	8.958–11.042	<0.001	<0.001	1.445 (1.170–1.786)

P values were listed in the table. *4 patients with NSCLC NOS, 2 patients with large cell lung cancer NOS, and 4 patients with mixed type were not enrolled.